Access is opening up for Kiwis to a weight loss drug described as a game changer.  

Wegovy, made by pharma-co Novo Nordisk, will arrive in pharmacies next week.  

It's not funded by Pharmac, so users will have to pay and get a prescription for the weekly injectable. 

Calocurb CEO Sarah Kennedy told Ryan Bridge that people need to be aware of both the cost of the drug and the side effect.  

She says that over 70% of people using Wegovy will have gastrointestinal problems that range from nausea to diarrhoea, and over 70% of people regain the weight within a year. 

Kennedy says lifestyle changes need to be made as well as taking the drug. 

LISTEN ABOVE 

Access is opening up for Kiwis to a weight loss drug described as a game changer. &nbsp;
Wegovy, made by pharma-co Novo Nordisk, will arrive in pharmacies next week. &nbsp;
It's not funded by Pharmac, so users will have to pay and get a prescription for the weekly injectable.&nbsp;
Calocurb CEO Sarah Kennedy told Ryan Bridge that people need to be aware of both the cost of the drug and the side effect. &nbsp;
She says that over 70% of people using Wegovy will have gastrointestinal problems that range from nausea to diarrhoea, and over 70% of people regain the weight within a year.&nbsp;
Kennedy says lifestyle changes need to be made as well as taking the drug.&nbsp;
LISTEN ABOVE&nbsp;

A fresh and intelligent start to your day - catch the very latest international and domestic news developments, sport, entertainment and business on Early Edition with Ryan Bridge, on Newstalk ZB.

A fresh and intelligent start to your day - catch the very latest international and domestic news developments, sport, entertainment and business on Early Edition with Ryan Bridge, on Newstalk ZB.

Early Edition with Ryan Bridge

Sarah Kennedy: Calocurb CEO on Wegovy becoming available in New Zealand

https://api.omny.fm/orgs/7784f840-c291-422a-924b-ad9000bbad71/clips/247c3231-9ca7-4f4f-8f5a-b308017bc21b/transcript